

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Methylphenidate (QuilliChew ER)

#### Notes:

- ^ Adequate trial of a long-acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.
- \*\*Adequate trial of a short acting agent is further defined as wearing off that is not resolved by increasing the dose and the frequency to a minimum of twice daily OR clinically significant side effects related to the short-acting dosage form that cannot be resolved by adjusting the dose or timing.
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

**Initiation (new start) criteria:** Non-formulary **methylphenidate (QuilliChew ER)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed an adequate trial<sup>^</sup> of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) (must have at least partial response), unless allergy to an inactive ingredient
- Patient has failed an adequate trial<sup>^</sup> of dextmethylphenidate ER (Focalin XR), unless allergy to an inactive ingredient
- Patient has failed an adequate trial <sup>^</sup> of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
- Documented intolerance or contraindication to sprinkle formulations and is unable to swallow whole tablets

**Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously:** Non-formulary **methylphenidate (QuilliChew ER)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial<sup>^</sup> of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) (must have at least partial response), with a short-acting agent, unless allergy to an inactive ingredient
- Patient has failed an adequate trial<sup>^</sup> of dextmethylphenidate ER (Focalin XR), with a short-acting agent, unless allergy to an inactive ingredient
- Patient has failed an adequate trial <sup>^</sup> of a long-acting amphetamine product (Adderall XR, etc), with a short-acting agent, unless allergy to an inactive ingredient

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Methylphenidate (QuilliChew ER)

**Criteria for *new members entering Kaiser Permanente already taking the medication who have not been reviewed previously*:** Non-formulary methylphenidate (QuilliChew ER) will be covered on the prescription drug benefit when the following criteria are met:

- Patient is over 21 year of age
  - Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
  - Patient has failed an adequate trial^ of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) (must have at least partial response), unless allergy to an inactive ingredient
  - Patient has failed an adequate trial^ of dexamethylphenidate ER (Focalin XR), unless allergy to an inactive ingredient
- OR -**
- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD) and patient is age 6 to 20 years old and stable on medication